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Abstract
Despite the characteristic etiologies and phenotypes, different brain disorders rely on common pathogenic events.
Glutamate-induced neurotoxicity is a pathogenic event shared by different brain disorders. Another event occurring in
different brain pathological conditions is the increase of the extracellular ATP levels, which is now recognized as a
danger and harmful signal in the brain, as heralded by the ability of P2 receptors (P2Rs) to affect a wide range of brain
disorders. Yet, how ATP and P2R contribute to neurodegeneration remains poorly defined. For that purpose, we now
examined the contribution of extracellular ATP and P2Rs to glutamate-induced neurodegeneration. We found both
in vitro and in vivo that ATP/ADP through the activation of P2Y1R contributes to glutamate-induced neuronal death in
the rat hippocampus. We found in cultured rat hippocampal neurons that the exposure to glutamate (100 µM) for 30
min triggers a sustained increase of extracellular ATP levels, which contributes to NMDA receptor (NMDAR)-mediated
hippocampal neuronal death through the activation of P2Y1R. We also determined that P2Y1R is involved in
excitotoxicity in vivo as the blockade of P2Y1R significantly attenuated rat hippocampal neuronal death upon the
systemic administration of kainic acid or upon the intrahippocampal injection of quinolinic acid. This contribution of
P2Y1R fades with increasing intensity of excitotoxic conditions, which indicates that P2Y1R is not contributing directly
to neurodegeneration, rather behaving as a catalyst decreasing the threshold from which glutamate becomes
neurotoxic. Moreover, we unraveled that such excitotoxicity process began with an early synaptotoxicity that was also
prevented/attenuated by the antagonism of P2Y1R, both in vitro and in vivo. This should rely on the observed
glutamate-induced calpain-mediated axonal cytoskeleton damage, most likely favored by a P2Y1R-driven increase of
NMDAR-mediated Ca2+ entry selectively in axons. This may constitute a degenerative mechanism shared by different
brain diseases, particularly relevant at initial pathogenic stages.
Introduction
The different brain disorders present characteristic
etiologies and phenotypes, and are underlined by dis-
tinctive pathogenic mechanisms. Yet, both acute and
chronic brain diseases present glutamate excitotoxicity as
a key pathogenic event in the development of neurode-
generation1–3. Glutamate-induced neuronal damage
involves an abnormal Ca2+ influx mainly mediated by
NMDA receptors (NMDARs)4,5. This Ca2+ overload then
leads to the activation of calpains and other proteases
mediating cytoskeleton damage6, paralleled by reactive
oxygen species generation, mitochondrial dysfunction,
and subsequent neuronal apoptosis7–10.
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Another event systematically occurring in different
brain disorders is the increase of the extracellular ATP
levels, which is now recognized as a danger and harmful
signal in the brain11, as heralded by the ability of ATP P2
receptors (P2Rs) to affect different brain pathologies12. In
particular, there is growing evidence that the antagonism
of P2X7R affords neuroprotection in a wide range of brain
disorders mainly through the control of neuroinflamma-
tion13. Attention has also been directed to P2Y1Rs as their
antagonism affords neuroprotection namely in ische-
mia14,15 or trauma16. P2Y1R-mediated control of brain
damage has been attributed to the control of astro-
cytes16,17. However, P2Y1Rs are also located in neurons
and targeted to synapses where they can modulate neu-
ronal function through the control of neurotransmitter
release18,19, NMDARs20, or calcium and potassium
channels21,22. This P2Y1R-driven neuromodulation seems
to be prominent in pathological conditions23,24, and was
shown to control neuronal damage in ischemia15. The
contribution of ATP to neuropathological conditions may
further entail other P2Rs12. Thus, there is now compelling
evidence for the contribution of extracellular ATP and
P2Rs to the pathogenesis of a wide range of neurological
disorders. Yet, the mechanisms through which extra-
cellular ATP and P2Rs contribute to neurodegeneration
remains ill defined. We now focused in a process common
to different brain disorders, glutamate-induced neuro-
toxicity, to examine the contribution of extracellular ATP
and P2Rs to neurodegeneration. We found in vitro and
in vivo that extracellular ATP/ADP through the activation
of P2Y1R catalyzes glutamate-induced synaptic loss and
latter neuronal death in the hippocampus and the
revealed underlying mechanism of action may constitute a
new common mechanism in brain diseases.
Results
Extracellular ATP and P2Y1R activation are required for
glutamate-induced degeneration of rat hippocampal
neurons
The exposure of rat hippocampal neurons to glutamate
(30–100 μM) for 30 min induced a significant increase in
neuronal death 24 h later (Fig. 1a, b). Glutamate (100 µM)
Fig. 1 Extracellular ATP and P2Y1Rs are required for glutamate-induced neuronal death. a Rat hippocampal neurons were exposed to
glutamate (100 µM) for 30 min, which induced a significant increase in cell death (PI—propidium iodide incorporation) 24 h later. The mean ± SEM
percentage of dead cells was quantified from 8 to 12 cultures analyzing 300 cells per culture. Scale bar, 200 µm. ***p < 0.001 one-way ANOVA with
Sidak’s test for time-matched comparisons. b Glutamate-induced neuronal death at 30 and 100 µM. *p < 0.05 and **p < 0.01 one-way ANOVA with
Dunnet’s test vs. untreated. c Glutamate exposure induced a sustained increase of the extracellular levels of ATP. Data are expressed as the fold
change in the levels of ATP in the culture media (mean ± SEM) vs. untreated; *p < 0.05 and **p < 0.01, one-sample t test (hypothetical value of 1). d
Glutamate-induced neuronal death was not observed either in the presence of apyrase (5 U/mL) or PPADS (10 µM; P2R antagonist); e it persisted in
the presence of Brilliant Blue G (BBG; 100 nM; P2X7R antagonist) or TNP-ATP (10 μM; P2X1-3-containing receptors antagonist); f was prevented by
Reactive Blue 2 (RB2; 10 μM; P2YR-preferring antagonist), by MRS2179 (10 µM; P2Y1R antagonist); and g by MRS2500 (0.1 and 1 µM; P2Y1R antagonist).
h In the presence of apyrase, ADPβS (5 µM; agonist of P2Y1,12,13Rs) restored glutamate-induced neuronal death, an effect prevented by MRS2179.
Data are mean ± SEM percentage of dead cells quantified from 3 to 8 cultures analyzing 300 cells per culture. *p < 0.05 and ***p < 0.001 one-way
ANOVA with Sidak’s test for glutamate vs. untreated
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triggered a sustained increase of the extracellular levels of
ATP early on, prior to frank neuronal degeneration
(Fig. 1c). The removal of extracellular ATP/ADP by
apyrase (5 U/mL) was sufficient to abrogate glutamate-
induced neuronal death (Fig. 1d). A similar neuropro-
tection was observed in the presence of the P2R antago-
nist, PPADS (Fig. 1d). Neither the selective antagonist of
P2X7R, brilliant blue G, nor the antagonist of P2X1-3-
containing receptors, TNP-ATP, mimicked this neuro-
protection (Fig. 1e). Instead, the preferring P2YR
antagonist, reactive blue 2, and the selective P2Y1R
antagonist MRS2179 abrogated glutamate-induced neu-
ronal death (Fig. 1f). Similar neuroprotection was
observed with another P2Y1R antagonist, MRS2500, re-
enforcing that the neuroprotection observed is due to the
blockade of P2Y1R (Fig. 1g). This neuroprotection by
Fig. 2 Pharmacological blockade of P2Y1Rs attenuates seizure-induced neurodegeneration in the rat hippocampus. a The intraperitoneal
(i.p.) administration of 10 mg/kg of kainate (KA) in rats caused convulsive period of circa 2 h, which induced hippocampal neuronal death 24 h later,
measured by FluoroJadeC-positive cells (FJC+), both in CA1, CA3, and dentate gyrus (DG) regions, as depicted in the representative images (scale bar,
200 µm) and quantified in the histogram. The hippocampi of animals injected with saline were absent of FJC+ cells. The number of FJC+ cells
induced by KA was significantly attenuated by the prior i.c.v. injection of 1 nmol MRS2500 (15 min before KA injection), in DG and CA1, also showing a
reduction tendency in CA3 region (p= 0.0815). The data are expressed as the number of FJC+ cells per slice (mean ± SEM) quantified from 4 animals
per group and analyzing 12 coronal sections separated successively by 240 µm representing the entire hippocampus from each animal. *p < 0.05
one-way ANOVA with Sidaks’s test. b Western blot of calpain substrates spectrin and CRMP2 in hippocampal protein extracts prepared 24 h after
saline/KA injection. KA-injected animals displayed an increase of the percentage of spectrin breakdown products (SBDPs) with an apparent molecular
weight of ~145 kDa, and of the truncated form of CRMP2 (CRMP255 kDa). The prior injection of MRS2500 attenuated or prevented the calpain-
mediated cleavage of spectrin or CRMP2, respectively. Data are mean ± SEM of the relative percentage of Spectrinfull-length/SBDPs and CRMP2A+B/
CRMP255 kDa (n= 4). **p < 0.01 and ****p < 0.0001 one-way ANOVA with Sidak’s test for KA vs. saline.
##p < 0.01 and ###p < 0.001 two-way ANOVA
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P2Y1R blockade was observed in neurons both at 7 days
in vitro (DIV7) and 14 days in vitro (DIV14). We further
observed that in the presence of apyrase, glutamate neu-
rotoxicity is restored by the addition of ADPβS (5 µM), an
agonist of P2Y1, 12, 13 receptors, an effect prevented by
the blockade of P2Y1R with MRS2179 (Fig. 1h). These
results show that ATP/ADP through the activation of
P2Y1R is involved in glutamate-induced neuronal death.
Blockade of P2Y1R attenuates seizure-induced
hippocampal neurodegeneration
To appraise if P2Y1R is involved in excitotoxicity
in vivo, we used the systemic administration of kainic acid
(KA), a widely used rat model of temporal lobe epilepsy,
which is accompanied by hippocampal degeneration25
and used as an in vivo model of excitotoxicity26.
Accordingly, neuronal loss (Fluoro-Jade C (FJC)-positive
staining) both in CA1, CA3, and DG regions (Fig. 2a) was
present 24 h after the intraperitoneal injection of KA, in
animals that experienced at least stage III in the Racine’s
scale27. A single intracerebroventricular (i.c.v.) injection of
MRS2500 (1 nmol) 15 min prior to KA administration
significantly decreased the number of FJC-positive cells in
CA1 and DG, also displaying a decreasing tendency for
the CA3 region (Fig. 2a). MRS2500 did not modify seizure
behavior. These data show that P2Y1R antagonism is
neuroprotective against excitotoxicity also in vivo.
We also observed an increased immunoreactivity of the
145 kDa spectrin breakdown product (SBDP) associated
with calpain-mediated cleavage in the hippocampi from
KA-injected rats (Fig. 2b), as previously reported28 and
consistent with status-epilepticus-induced, calpain-
Fig. 3 Glutamate induces cell death in rat hippocampal neurons through the activation of NMDARs in a P2Y1R-dependent manner. a The
exposure of rat cultured hippocampal neurons to glutamate (100 µM) for 30 min induced a decrease in cell viability 24 h later, which was prevented
by the NMDAR antagonist MK801 and mimicked by the exposure to NMDA (100 µM) for 30 min. Data are mean ± SEM of the percentage of MTT
reduction vs. respective control, quantified from 4 to 7 different cultures, analyzing triplicates per condition per culture. **p < 0.01 one-sample t test
(hypothetical value of 100); #p < 0.05 unpaired t test for glutamate+MK801 vs. glutamate alone. b NMDA-induced neuronal death was prevented
either by PPADS (10 µM) or MRS2179 (10 µM). The data are mean ± SEM of the percentage of dead cells (propidium iodide incorporation) quantified
from four cultures analyzing 300 cells per condition per culture. ***p < 0.001 one-way ANOVA with Sidak’s test for NMDA vs. untreated. c The
intrahippocampal administration of 120 nmol of quinolinic acid (QA) in rats caused hippocampal neuronal death 24 h later, measured as Fluoro-Jade
C-positive cells (FJC+), as depicted in the representative images (scale bars, 200 µm) and quantified in the histogram. The co-administration of 1 nmol
of MRS2500 significantly attenuated the number of FJC+ cells in DG and CA3 regions. The mean ± SEM number of FJC+ per slice was quantified from
4 animals per group and analyzing 12 coronal sections separated successively by 240 µm and representing the entire hippocampus from each
animal. *p < 0.05 one-way ANOVA with Sidak’s test
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mediated neuronal death29. Increased calpain activity was
further confirmed by the observed cleavage of CRMP2
protein into CRMP255 kDa product, previously shown to
be triggered under excitotoxic conditions in vitro30
(Fig. 2b). The administration of MRS2500 attenuated or
prevented the calpain-mediated cleavage of spectrin or
CRMP2, respectively (Fig. 2b). These findings not only
confirm the involvement of P2Y1R in excitotoxicity-
mediated neurodegeneration in vivo, but also provide a
link between P2Y1R and calpain activity.
P2Y1R is required for glutamate-induced and NMDAR-
mediated rat hippocampal neuronal loss
Glutamate-induced hippocampal neuronal death was
prevented by the NMDAR antagonist MK801 (Fig. 3a).
Accordingly, a similar decrease of neuronal viability was
observed when rat hippocampal neurons were exposed to
NMDA (100 μM) instead of glutamate (Fig. 3a). These
results confirm that glutamate-induced neuronal death is
mediated by NMDARs, consistent with previous
reports4,5. The NMDA-induced hippocampal neuronal
death was prevented by P2Y1R antagonism (Fig. 3b).
Rat hippocampal neurodegeneration observed upon KA
injection and attenuated by P2Y1R blockade (Fig. 2a) has
been shown to be essentially dependent on NMDARs31.
We further confirmed that P2Y1R antagonism affords
neuroprotection against NMDAR-induced toxicity
in vivo, by the observation of an attenuation of neuronal
death induced by an intrahippocampal administration of
the agonist of NMDARs quinolinic acid (QA, 120 nmol),
with the co-injection of MRS2500 (Fig. 3c).
These results show that glutamate-induced neurotoxi-
city involves NMDARs and NMDAR-induced neuronal
death also involves P2Y1R activation.
The contribution of P2Y1R to glutamate-induced neuronal
death fades with increasing severity of the excitotoxic
stimuli
P2Y1Rs are expressed both in rat hippocampal neurons
and astrocytes (e.g. Rodrigues et al.18 and Bowser and
Fig. 4 The contribution of P2Y1Rs to glutamate-induced neuronal death decreases with increasing severity of excitotoxic conditions. a
Representative images of rat hippocampal primary cultures showing immunoreactivity for P2Y1Rs in neurons (MAP2—dendritic marker; SMI31—
axonal marker) and astrocytes (GFAP+). Scale bars, 20 µm. b Primary hippocampal cultures incubated with AraC (2 µM) at DIV2–5 to inhibit astrocyte
proliferation presented a reduced number of GFAP+ cells (DIV7), as depicted in the representative images (scale bar, 50 µm) and quantified in the left
histogram. In cultures incubated with AraC, the exposure to glutamate (100 µM) for 30 min induced a significant increase in neuronal death (PI
incorporation) observed 24 h later, which was attenuated by the presence of MRS2500 (1 µM). Data are mean ± SEM percentage of viable cells vs.
respective control, quantified from four different cultures analyzing 300 cells per culture per condition. c The exposure of rat cultured hippocampal
neurons to NMDA (100 µM) for 30 min induced a decrease in cell viability 24 h later evaluated both by MTT reduction (upper graph) and PI
incorporation (lower graph), which was not observed in the presence of MRS2500 (1 µM). The decrease in cell viability observed 24 h after the
exposure to NMDA (100 µM) for 12 h was not modified by MRS2500. Upper graph—data are mean ± SEM of the percentage of MTT reduction vs.
respective control, quantified from 5–8 different cultures, analyzing triplicates per condition per culture. Lower graph—data are mean ± SEM of the
percentage of dead cells (PI incorporation) vs. respective control quantified from four cultures analyzing 300 cells per condition per culture. *p < 0.05,
**p < 0.01, and ***p < 0.001 one-sample t test (hypothetical value of 100); ##p < 0.01 unpaired t test; &p < 0.05, &&p < 0.01, and &&&p < 0.001 two-way
ANOVA with Sidak’s multicomparison test
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Khakh32). Accordingly, we could detect immunoreactivity
for P2Y1R both in cultured neurons and astrocytes
(Fig. 4a). Therefore, we evaluated the putative contribu-
tion of astrocytic P2Y1R to glutamate-induced neuro-
toxicity. Despite the fact that we observed a
neuroprotection by P2Y1R blockade not only in DIV14
but also in DIV7, where the percentage of astrocytes is
relatively low (<15%), we evaluated the contribution of
P2Y1R to glutamate-induced neuronal death now in cul-
tures exposed to cytosine 1-β-D-arabinofuranoside (AraC)
to inhibit astrocyte proliferation (Fig. 4b). In these
conditions, we could observe that the blockade of P2Y1R
with MRS2500 only attenuated glutamate-induced neu-
ronal death. This shows that neuronal P2Y1Rs contribute
to glutamate-induced neurotoxicity. But it also suggests
for a contribution of astrocytic P2Y1Rs. However, the
neuronal death caused by glutamate exposure was con-
siderably higher in cultures in which astrocyte prolifera-
tion was inhibited (~45% neuronal death; Fig. 4b) in
comparison with regular primary cultures (20–25%), most
likely due to the lack of glutamate uptake by astrocytes.
This also raises the possibility that the contribution of
Fig. 5 Pharmacological blockade of P2Y1Rs increases NMDAR-induced current density in rat hippocampal neurons. a [3H]Aspartic acid
saturation-specific binding curve to NMDARs in rat hippocampal synaptosomal membranes with a Bmax of 923.9 ± 110.5 fmol/mg protein and with a
KD of 199 ± 48 nM (mean ± SEM; n= 7). The non-NMDAR binding was defined in the presence of D-AP-5 (30 µM). Neither MRS2179 (10 µM) nor
MRS2500 (10 µM) affected the Bmax and the KD values of [
3H]aspartic acid specific binding (bar graphs; n= 6). b Representative traces of NMDA-
induced inward currents in rat hippocampal neurons in the absence and in the presence of MRS2179 (10 µM). c Rat hippocampal neurons exposed
to MRS2179 (10 µM) for 30 min presented a higher NMDA-induced current density in relation to untreated cells. Data are expressed as the mean ±
SEM of peak NMDA-induced current density (pA/pF). *p < 0.05 unpaired t test (n= 6–7)
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P2Y1R may be reduced with more intense excitotoxic
conditions. Accordingly, while the presence of MRS2500
prevented the decrease of cell viability observed 24 h after
the exposure to NMDA (100 µM) for 30 min, it failed to
modify the neuronal death caused by the exposure to
NMDA (100 µM) for 12 h (Fig. 4c).
These results show that neuronal P2Y1Rs contribute to
glutamate-induced neuronal death, and also indicate that
this contribution fades with more intense excitotoxic
conditions.
P2Y1R induces an increase in NMDAR-mediated Ca2+ entry
selectively at the axonal compartments
Neither MRS2500 nor MRS2179 affected the ligand
binding to NMDARs (Fig. 5a) or modified NMDARs
activation and current (Fig. 5b). This discarded any
eventual off-target action of the P2Y1R antagonists tested
directly on NMDARs, which could be affording the neu-
roprotection observed. Hence, we hypothesized that
P2Y1R could be contributing to glutamate-induced neu-
rodegeneration by inducing an increase in the density of
NMDARs and consequently favoring a toxic NMDAR-
mediated Ca2+ entry. Surprisingly, rat hippocampal neu-
rons incubated for 30min with MRS2179 displayed a
higher NMDAR-induced current density in comparison
with untreated neurons (Fig. 5c), which is at odds with the
neuroprotection afforded by the P2Y1Rs antagonism
against NMDARs toxicity.
As whole-cell patch-clamp recordings essentially pro-
vide total cell current, this analysis could be masking any
eventual subcellular-specific P2Y1R-driven increase in
NMDARs. To test this hypothesis, we first evaluated the
subcellular distribution of P2Y1Rs in rat hippocampal
neurons. P2Y1R immunoreactivity was found in the soma
(Fig. 6a), dendrites, and axons (Fig. 6b), as similarly
described in mice hippocampal neurons33. The co-
localization of P2Y1R with synaptophysin also indicated
the presence of P2Y1Rs in some synaptic contacts (~20%
of synaptophysin puncta; Fig. 6c). This subcellular
localization of P2Y1Rs was functionally confirmed by Ca2
+ imaging. ADPβS-induced Ca2+ rises both in the soma
and dendrites, and predominantly in distal axons, both
absent in the presence of MRS2179 (Fig. 6d).
Using Ca2+-imaging analysis, neurons pre-incubated
with MRS2179 for 30min displayed a higher NMDA-
induced Ca2+ transients both in the soma and dendrites
(Fig. 6e, f), similar to the observed in patch-clamp
recordings (Fig. 5c). Accordingly, the cells pre-incubated
with ADPβS presented a lower NMDA-induced Ca2
+-transients in the soma and dendrites, an effect pre-
vented by MRS2179 (Fig. 6e, f). In contrast, the cells
incubated with ADPβS presented ~2-fold higher NMDA-
induced Ca2+ transients in axonal compartments (Fig. 6g),
an effect prevented by MRS2179 (Fig. 6g). MRS2179
per se did not modify NMDA-induced Ca2+ transients in
axons. Ca2+ transients triggered by the chemical depo-
larization with KCl (30 mM) were not significantly mod-
ified by the pharmacological manipulation of P2Y1Rs in
any of the cellular compartments (Fig. 6e–g) discarding
the involvement of a P2Y1R-driven regulation of voltage-
gated calcium channels (VGCCs). Hence, these results
show that P2Y1R modulates in a bidirectional and
subcellular-specific manner the NMDA-induced Ca2+
entry, decreasing it in the soma and dendrites and
increasing it in the axons.
Blockade of P2Y1R prevents glutamate-induced initial
axonal cytoskeleton damage
Neuritic degeneration caused by excitotoxicity precedes
cell soma demise and involves calpain activity34. Calpain-
mediated neuronal injury is associated with NMDAR-
mediated Ca2+ overload4,35. Thus, the identification of a
P2Y1R-driven increase in NMDAR-mediated Ca2+ entry
selectively at the axons prompted the hypothesis that
P2Y1Rs may be contributing to neurodegeneration by
promoting a toxic increase in axonal NMDAR-mediated
Ca2+ entry and subsequent calpain-mediated axonal
cytoskeleton damage. Indeed, in rat hippocampal neurons,
(see figure on previous page)
Fig. 6 P2Y1Rs differentially regulate NMDARs in a subcellular-specific manner. a–c Representative images of rat hippocampal neurons showing
the immunoreactivity for P2Y1Rs in a the cell body, b dendrites (MAP2—dendritic marker), predominantly in proximal regions, axons (SMI31—axonal
marker), and c nerve terminals (synaptophysin—synaptic marker). d Representative traces of Ca2+-imaging analysis in rat hippocampal neurons
(loaded with Fluo-4) showing [Ca2+]i transients represented by fluorescence increase (ΔF488) induced by ADPβS (5 µM) and abrogated by MRS2179
(10 µM), recorded in dendrites (purple), soma (blue), and in proximal and distal axon (yellow-green and magenta, respectively). Scale bars, 10 µm. e–g
Ca2+ imaging of rat hippocampal neurons previously exposed to untreated conditions, ADPβS (5 µM), MRS2179 (10 µM), or ADPβS+MRS2179 for 30
min, and challenged with NMDA (100 µM) and KCl (30 mM). In neurons previously exposed to ADPβS, the perfusion of NMDA for 1 min induced
lower Ca2+ transients in e the soma and f dendrites, and a higher Ca2+ rise in g axons in relation to untreated cells, as depicted in the average traces
of fluorescence intensity and quantitatively summarized in the histograms. These ADPβS-induced effects were not observed in the presence of
MRS2179, which per se induced a higher NMDA-induced Ca2+ transients in the soma and dendrites, but not in axons. The chemical depolarization
with KCl induced similar Ca2+ transients in the neurons from each condition. The mean ± SEM of ΔF488 was quantified from four different cultures
and analyzing a minimum of eight cells per culture per condition. *p < 0.05 and **p < 0.01 vs. untreated and ###p < 0.001 between indicated bars,
one-way ANOVA with Sidak’s test. NS nonsignificant
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we detected immunoreactivity with an antibody that binds
specifically the product resulting from the cleavage of
spectrin by calpain I36, 1 h after the exposure to glutamate
(Fig. 7a). This is in agreement with the previous obser-
vation of fast calpain activation, peaking 30min after the
excitotoxic insult37. Surprisingly, this immunoreactivity
was solely observed in structures immunostained with
SMI31, which reacts predominantly with phosphorylated
neurofilament H present in axons, but absent in MAP2-
positive structures (dendrites). Furthermore, we could
observe a decreased SMI31 immunoreactivity in the seg-
ments immunopositive for SBDPs (Fig. 7b, c). This shows
a match between calpain activity and axonal cytoskeleton
damage, particularly showing the degradation of
neurofilaments, which are calpain substrates38. The
glutamate-induced immunoreactivity for SBDPs was not
observed in the presence of MRS2179 (Fig. 7a). These data
show that glutamate induces calpain activation and
cytoskeletal damage initially in axons in a P2Y1R-
dependent manner.
P2Y1 receptor activation contributes for glutamate-
induced early synaptic loss
Synaptic dysfunction/loss is a primordial step in the
cascade of neurodegenerative events in different brain
disorders39. Accordingly, we observed a significant
reduction of the synaptic density in rat hippocampal
neurons 12 h after glutamate exposure gauged both by
Fig. 7 Glutamate induces an initial calpain activation and cytoskeleton degeneration in the axon of rat hippocampal neurons in a P2Y1R-
dependent manner. a Representative images of immunocytochemical analyses of rat hippocampal neurons (DIV14) showing spectrin breakdown
products (SBDPs—magenta), 1 h after glutamate exposure (100 µM; 30 min) in axons (SMI31; axonal marker; cyan), but not in dendrites (MAP2;
dendritic marker; green), which was not observed in the presence of the selective antagonist of P2Y1Rs, MRS2179 (10 µM). b Representative image
depicting a coincident reduction of SMI31 immunoreactivity (p-neurofilaments) with the labeling of SBDPs in the axonal structure defined by the
yellow dashed line between points a and b, as quantitatively represented in the lower graph. c In the neurons exposed to glutamate, the axonal
structures immunopositive for SBDPs present a reduced average in the fluorescence intensity of SMI31 in comparison to axonal segments negative
for SBDPs. Data are expressed as the median with interquartile range of the average fluorescence intensity of SMI31 quantified from 36 segments
with a minimum length of 50 µm from axonal structures without or with SBDP immunoreactivity. Dots represent single segments. ***p < 0.001
Mann–Whitney test. In b, c, the fluorescence intensities from the 8-bit images (256-color scale) were directly converted into a 0–1 scale, being the
absence of fluorescence set as 0 and the maximum intensity set as 1. Scale bars, 20 µm
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morphological analysis (Fig. 8a) and by a reduction of the
frequency of miniature excitatory post-synaptic currents
(mEPSCs; Fig. 8b, c). These data demonstrate a synapto-
toxicity induced by glutamate prior to frank neuronal
degeneration, only significant 24 h later (Fig. 1a). This
glutamate-induced synaptic loss also involves P2Y1R
since it was prevented by the presence of MRS2179
(Fig. 8a–c). We also observed a decrease in the amplitude
of mEPSCs in neurons exposed to glutamate, which was
also P2Y1R-dependent (Fig. 8d).
A decrease of the immunoreactivity of synaptic markers
was also observed in the rat hippocampus 24 h upon KA
injection. A significant reduction of the immunoreactivity
of general synaptic markers sintaxin1A and synaptophysin
(Fig. 8e), the glutamatergic synaptic markers vGluT1 and
PSD-95 (Fig. 8f), and the GABAergic synaptic markers
vGAT and gephyrin (Fig. 8g) was appraised. The single
i.c.v. injection of MRS2500 15min prior to KA adminis-
tration prevented/attenuated this seizure-induced
decrease in the immunoreactivity of the synaptic mar-
kers (Fig. 8e–g). These data show the existence of a
synaptic loss induced by excitotoxicity prior to neuronal
death, which also involves P2Y1R activation.
Discussion
In the present study, we demonstrate both in vitro and
in vivo that excitotoxicity entails extracellular ATP/ADP
and P2Y1R activation. We found that glutamate triggers a
Fig. 8 Glutamate induces synaptic loss prior to neuronal death in a P2Y1R-dependent manner. a Rat hippocampal neurons (DIV14) exposed
to glutamate (100 µM; 30 min) display a decrease in the density of the synaptophysin puncta per dendritic length after 12 h, an effect not observed in
the presence of MRS2179 (10 µM), as depicted in the representative confocal images (scale bar, 10 µm). Data are mean ± SEM of synaptophysin
puncta per dendritic length quantified from four different cultures analyzing a minimum of 2000 µm of MAP2+ structures from two independent
coverslips per condition, per culture. b Representative traces of mEPSC recorded in rat hippocampal neurons (DIV14) 12–14 h after the exposure to
glutamate (100 µM; 30 min) either in the absence or in the presence of MRS2179 (10 µM). c, d Cumulative histograms (left) and pooled data (right) of
the average of c instantaneous frequency or d peak amplitude of mEPSCs. Pooled data are mean ± SEM of the average frequency/amplitude of
mEPSCs calculated from 180 s bins recorded from 11 to 15 neurons per condition. *p < 0.05 and **p < 0.01 Kruskal–Wallis with Dunn’s test for
frequency and one-way ANOVA with Sidak’s test for amplitude. e Western blot analysis of general synaptic markers, synaptophysin and syntaxin1A, f
glutamatergic synaptic markers, vGluT1 and PSD-95 and g GABAergic synaptic markers, gephyrin and vGAT, in total protein extracts prepared from
hippocampi of rats previously injected i.p. with saline or kainate (KA,10 mg/kg). Hippocampal protein extracts of the animals injected with KA
displayed a significant decrease in the immunoreactivity of all the synaptic proteins evaluated, except for gephyrin (p= 0.1205), in comparison with
saline-injected mice, as depicted in the representative Western blots (in left) and summarized in the histograms (in right). The i.c.v. injection of 1 nmol
of MRS2500 15 min prior to the administration of KA prevented or attenuated the decrease in the immunoreactivity of the different synaptic markers.
MRS2500 per se did not cause any significant modification in the density of the synaptic markers. Data are percentage (mean ± SEM) of the ratio of
immunoreactivity synaptic markers/loading control relative to the average ratio obtained in samples from aCSF/Sal group (n= 4). *p < 0.05, **p <
0.01, and ***p < 0.001 one-way ANOVA with Sidak’s post hoc test for KA vs. respective saline
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sustained increase of extracellular ATP levels, which
contributes for glutamate-induced hippocampal neuronal
death through the activation of P2Y1R. This contribution
of P2Y1Rs fades with increasing intensity of excitotoxic
conditions. This indicates that P2Y1R is not contributing
directly to neurodegeneration, rather behaving as a cata-
lyst of excitotoxicity by decreasing the threshold from
which glutamate becomes neurotoxic. Moreover, we
found that excitotoxicity began with an early synapto-
toxicity that was also prevented/attenuated by the antag-
onism of P2Y1R, both in vitro and in vivo. This should be
due to a P2Y1R-driven subcellular-specific gain-of-
function of NMDARs, favoring an increase to toxic
levels of NMDAR-mediated Ca2+ entry, leading to
calpain-mediated axonal cytoskeleton damage.
Several evidences support the involvement of extra-
cellular ATP and P2Rs in the pathogenesis of a wide range
of brain disorders. Glutamate-mediated excitotoxicity is a
pathogenic event associated with different acute and
chronic brain disorders2. Thus, the present data re-
enforces a prominent role of ATPergic signaling in brain
pathological conditions. Besides, although a major focus
has been dedicated to P2X7R probably acting through the
control of neuroinflammation13, our data pinpoints a
particular pathological role of P2Y1Rs.
P2Y1Rs have been shown to be involved in neurode-
generation in ischemic conditions14 and trauma16. The
neuroprotection afforded by P2Y1R blockade in those
pathological conditions has been attributed to the control
of astrocytic function14,16,17. On the other hand, P2Y1Rs
are expressed in neurons18,32 and it has been shown that
neuronal P2Y1R may also directly affect brain damage15.
In the present study, in low-astrocyte cultures, we could
still observe neuroprotection afforded by P2Y1R blockade,
supporting the involvement of neuronal P2Y1Rs (Fig. 4b).
The observation of a partial neuroprotection by the
antagonism of P2Y1Rs in these cultures could also indi-
cate for an additional contribution of astrocytic P2Y1Rs.
The ability of P2Y1Rs to induce glutamate release from
astrocytes40, subsequently activating NMDAR on neu-
rons41 could be a mechanism through which astrocytic
P2Y1Rs could be promoting neuronal death. Yet, ADPβS
is not neurotoxic per se. Besides, in such scenario, the
removal of astrocytes would be expected to have a pro-
survival action. Instead, we observed a higher cell death.
This is most likely due to the lack of glutamate uptake by
astrocytes, which could mask a pro-survival effect arising
from the removal of neurotoxic astrocytic P2Y1Rs.
However, we also observed that the blockade of P2Y1Rs
failed to modify the neuronal death caused by a more
prolonged excitotoxic stimulus (Fig. 4c) showing a
decreased impact of P2Y1Rs with more intense excito-
toxic conditions. Thus, although not fully discarding a
partial contribution of the P2Y1Rs expressed in
astrocytes, the available data favors a prominent involve-
ment of neuronal P2Y1Rs, also indicating that P2Y1Rs are
not directly neurotoxic, rather behaving as promoters of
the conditions that favor a neurotoxic action of glutamate.
The contribution of P2Y1Rs as promoters rather than
effectors in excitotoxicity is more in agreement with the
observation of attenuation rather than a prevention of the
seizure-induced or NMDAR-mediated hippocampal
degeneration by the blockade of P2Y1Rs (Figs. 2a and 3c).
Besides, it also agrees with the different neuroprotective
profiles displayed by P2Y1R antagonism in each model,
attenuating neuronal death in DG and CA3 regions in QA
model (Fig. 3c), whereas in the KA model it afforded
neuroprotection in DG and CA1, displaying a lower effect
in CA3 (Fig. 2a). This may not be due to a region-specific
neuroprotective action of the blockade of P2Y1Rs, as it
was neuroprotective in CA3 in the QA model and in CA1
in the KA model. Instead, it may be due to the well-known
selective vulnerability of hippocampal neurons to different
excitotoxins, related with the distribution of the different
ionotropic glutamate receptors across the different hip-
pocampal regions42. In the QA model, NMDAR-mediated
neurodegeneration is triggered by direct activation of
NMDARs, whereas in the KA model NMDAR-mediated
neuronal death is elicited indirectly through the increased
neuronal excitability driven by AMPA and KA recep-
tors31. For instance, KA administration induces hippo-
campal damage primarily in CA343, a region particularly
enriched with KARs44. As the contribution of P2Y1Rs
fades with increasing excitotoxic stimulus, the neuro-
protection afforded by P2Y1R antagonism is expected to
be reduced/absent in regions where the excitotoxic sti-
mulus is more severe, as observed in the CA3 region in
the KA model.
Glutamate-induced neurotoxicity is well associated with
intracellular Ca2+ rise4, mostly associated with the Ca2+
influx through NMDARs rather than non-NMDARs or
VGCCs45. Consistently, we observed that glutamate-
induced neurotoxicity was prevented by NMDAR block-
ade and mimicked by NMDAR agonism, which was also
dependent on P2Y1R activation (Fig. 3). Furthermore, cell
death has been mainly associated with the activation of
extrasynaptic NMDARs46. Yet, this notion of toxic
extrasynaptic NMDARs vs. pro-survival synaptic
NMDARs is under debate47 and may essentially depend
on the Ca2+ load mediated by NMDARs48. Regardless the
involvement of extrasynaptic and/or synaptic NMDARs,
the excessive activation of NMDARs has been indicated to
primarily damage post-synaptic structures. However, the
present results clearly point towards an initial degenera-
tion of axonal compartments upon the exposure to glu-
tamate before any detectable dendritic damage, raising
axonal degeneration as a primary degenerative event in
excitotoxicity. Such glutamate-induced axonal damage
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seems to be triggered by a P2Y1R-driven increased axonal
NMDARs since: (i) P2Y1Rs are predominantly located at
the axons (Fig. 6b, d); (ii) glutamate-induced axonal
cytoskeleton damage depends on P2Y1R activation
(Fig. 7a); (iii) P2Y1Rs increase NMDA-induced Ca2+
transients selectively at the axons (Fig. 6e–g); (iv) this
should be due to a P2Y1R-driven increase in axonal
NMDARs instead of a regulation of VGCCs. This view
agrees with previous evidence showing that the distal
axons are endowed with NMDARs49 and can be a direct
target for excitotoxicity50. In addition, the results obtained
further indicate that this increase of the axonal NMDARs
should only occur in pathological conditions as P2Y1R
blockade modified NMDA-induced Ca2+ transients in
dendrites and soma but not in axons. Only the pharma-
cological activation of P2Y1Rs modified axonal NMDARs.
Thus, in contrast to dendrites and soma, where there is a
constitutive tonic regulation of NMDARs by P2Y1Rs, as
previously observed in other preparations20, the P2Y1R-
driven increase of axonal NMDARs should only occur in
pathological conditions, most likely supported by a sus-
tained increase of the extracellular ATP levels (Fig. 1b).
Perhaps more surprisingly is the fact that the NMDAR-
mediated Ca2+ transients in axons are much smaller in
comparison to the observed both in dendrites and soma.
This suggests that the toxic action of NMDAR may not be
determined by the amount of Ca2+ entry. Instead, it may
essentially depend on the balance between the Ca2+ load
and the buffering capacity of the cell to preserve Ca2+
homeostasis, and/or on a more efficient coupling to
degenerative pathways.
Although there is not a clear evidence demonstrating a
causal relationship between axonal damage and synaptic
loss, axon degeneration is a phenomenon shared by both
acute and chronic neurodegenerative diseases51–53, which
are characterized by an initial synaptic dysfunction/loss and
neuritic degeneration prior to soma demise39,54. Preventing
axonal damage and synaptic loss rather than protecting cell
bodies has been proposed as the most effective therapeutic
strategy to prevent neurodegeneration52. This is heralded
by the observation in motor neuron disease models that
protecting cell bodies from death has no impact on disease
progression55, whereas the inhibition of axon degeneration
and synaptic loss attenuated neuronal apoptosis56. Thus,
although the degeneration of neuronal processes is
mechanistically independent of cell death pathways, not
involving caspase57,58, but rather calpain34,38, as also sup-
ported by the present data, the initial degeneration of axon
seems not only to precede but also to constitute a trigger of
apoptotic neuronal death. Accordingly, we observed that
MRS2179 applied 12 h after glutamate exposure, when
synaptic loss is evident in the absence of neuronal death,
did not prevent glutamate-induced cell death. Altogether,
these evidences point out the prevention of axonal damage
as the most promising therapeutic strategy to arrest brain
disorders53. We have now determined that axonal degen-
eration, at least in excitotoxic conditions, is favored by
P2Y1R by promoting calpain-mediated axonal cytoskeleton
damage, most likely reflecting a P2Y1R-driven increase of
axonal NMDAR-mediated Ca2+ entry. Interestingly, cal-
pains are also associated with the pathogenesis of different
brain diseases10. Thus, this novel pathway may constitute a
degenerative mechanism shared by different brain diseases,
particularly relevant at initial pathogenic stages.
The use of NMDAR antagonists as therapeutic strate-
gies cannot be exploited due to the vital roles of
NMDARs59. Also, the lack of tools to selectively manip-
ulate the downstream calpain activity precluded targeting
these proteases as a therapeutic strategy10. Our findings
now identify P2Y1Rs as a novel upstream potential ther-
apeutic target and prompt to consider the use of P2Y1R
antagonists as a promising strategy for therapeutic inter-
vention in neurodegenerative diseases, at least to delay
their onset/manifestation.
Materials and methods
Animals
Male Wistar rats (250–300 g; 8–10 weeks) were group
housed, maintained on a 12 h light/dark cycle, and
allowed food and water ad libitum. For the preparation of
primary neuronal cultures, male and female rat Wistar
embryos (E18) were used. All the procedures relating to
the handling and killing of animals were approved and
supervised by the Animal Care and Use Committee of the
Center for Neuroscience and Cell Biology, Portugal, and
of the Instituto de Neurociencias, CSIC-UMH, Spain, in
accordance with the European Commission (2010/63/
EU), FELASA and ARRIVE guidelines.
Primary rat hippocampal cultures
Primary hippocampal cell cultures from Wistar rat E18
embryos were prepared as described before60. In the low-
astrocyte cultures, cells were incubated with cytosine AraC
(Sigma-Aldrich, Sintra, Portugal) at a concentration of 2 µM
at DIV2–5. For cell viability assays, immunocytochemistry,
Ca2+imaging, and electrophysiological recordings, cells
were plated in glass coverslips at a density of 12,500 cells/
cm2. Cells were used both at DIV7 and DIV14, except for
synaptic density (morphological and electrophysiological
analysis) and SBDP immunoreactivity evaluation performed
only at DIV14, and in the cell viability assay in low-astrocyte
cultures performed only at DIV7.
In vitro cell viability assays
Rat hippocampal neurons were exposed to glutamate
(1–100 µM) or NMDA (100 μM) during 30min or 12 h.
The different drugs tested were added 15min before
glutamate/NMDA exposure and were present until the
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end of the experiment. Cell viability was then assessed at
different periods after the exposure of glutamate up to 24
h using a double staining with the fluorescent probes
propidium iodide (PI) and SYTO-13 (Molecular Probes,
Alfagene, Carcavelos, Portugal). Briefly, cells were loaded
for 3 min in Krebs buffer (in mM: NaCl 132, KCl 4, MgCl2
1.4, CaCl2 1, glucose 6, HEPES-Na 10, pH 7.4) containing
4 μM SYTO-13 and 4 μg/mL PI. Cells were then visua-
lized and images were acquired using an inverted fluor-
escence Zeiss Imager.Z2 microscope and the Axiovision
SE64 Rel.4.8 software (Zeiss, Grupo Taper, Sintra, Por-
tugal). Viable neurons present nuclei homogenously
labeled with Syto-13 (green fluorescent nuclei). In con-
trast, putative apoptotic neurons show condensed and
fragmented nuclei labeled with Syto-13 (primary apop-
tosis) or with Syto-13 plus PI (secondary apoptosis), and
necrotic neurons present intact nuclei labeled with PI
(dark, homogeneous, large red fluorescent nuclei). Each
experiment in different cell cultures were performed in
triplicate and cell counting was carried out in six fields per
coverslip analyzing a minimum number of 300 cells per
coverslip. Neuronal death was expressed as percentage of
non-viable cells compared to the total number of cells.
Cell viability was further assessed by Alamar Blue and 3-
[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) assays. Cultured rat hippocampal neurons
were incubated with Alamar blue dye at 10% (v/v) (Invi-
trogen, Alfagene) or MTT (0.5 mg/mL). In the Alamar
Blue assay, after 4 h incubation aliquots of the media were
collected from each well and absorbance of either reduced
(570 nm) or oxidized form (600 nm) was measured. The
relative change in reduction in the Alamar Blue assay
were considered equivalent to the relative change in cell
viability, as it is proportional to the number of viable cells
containing competent mitochondria. In the MTT assay,
after 2 h incubation, the insoluble purple product for-
mazan resulting from the reduction of MTT by NAD(P)
H-dependent oxidoreductases present in cells with viable
mitochondria was solubilized in dimethyl sulfoxide for 1 h
at room temperature, under agitation and protected from
light. The percentage of MTT reduced was measured by
the difference between the absorbances at 570 and 600
nm read in a spectrophotometer (Spectramax Plus 384,
Molecular Devices, UK). The percentage of reduction of
MTT was calculated comparing the difference of the
absorbance at 570 and at 600 nm of each sample. Control
wells containing medium only (no cells) were used to
subtract the background absorbance. Results are pre-
sented as percentage of control (wells incubated with
vehicle).
Extracellular ATP quantification
After the exposure of cultured hippocampal neurons to
glutamate (100 µM, 30 min), 50 μL of culture medium
were collected at different time points (3–24 h) from each
well and mixed with 50 μL of the luciferin-luciferase
bioluminescent ATP assay mix from Sigma (FLAAM).
The light emitted was quantified using a luminometer
(PerkinElmer Victor3, Villepinte, France) and ATP levels
were quantified using a calibration curve of ATP stan-
dards. The quantification in each condition and time-
point was performed in triplicates.
Single-cell Ca2+ imaging
Rat hippocampal neurons were loaded with Fluo-4 AM
(2 μM, 30min at 37 °C; Molecular Probes, Alfagene) in the
following medium (in mM): NaCl 160mM, KCl 2.5, CaCl2
1.8, glucose 10, HEPES 10, MgCl2 2 (pH 7.2). The cells
were then washed twice to remove remaining Fluo-4 AM
and mounted in a small perfusion chamber (Warner
Instruments, USA) in the stage of a Zeiss Axiovert 200
inverted fluorescence microscope (Zeiss) equipped with a
cooled CCD camera (Roper Scientific, Tucson, AZ, USA)
that allowed the acquisition of 12-bit images at a rate of 1
Hz using MetaFluor 5.0 software (Zeiss). Drugs were
applied to the cells in the same Krebs medium, except for
NMDA-induced Ca2+ transients in which MgCl2 was
omitted. Time-course data represents the average of
fluorescence intensity obtained in the regions of interest.
Electrophysiological recordings
NMDA-induced currents were recorded in rat hippo-
campal neurons at −60mV by whole-cell patch clamping
using an AxonPatch 200B amplifier (Molecular Devices)
or List EPC-7 amplifier. The borosilicate glass micropip-
ettes used had a resistance of 4–6MΩ and were filled with
the following internal solution (in mM): CsMeSO4 130,
CsCl 10, CaCl2 0.5, EGTA 5, HEPES 10, and NaCl 10 (pH
7.3 adjusted with CsOH). Cells were perfused with
extracellular solution containing 160mM NaCl, 2.5 mM
KCl, 1.8 mM CaCl2, 10 mM HEPES, 15 mM glucose, and
10 µM glycine (pH 7.4 adjusted with NaOH). All drugs
were daily prepared in extracellular solution and rapidly
perfused with a six channel perfusion valve control system
VC-77SP/perfusion fast-step SF-77B (Warner Instru-
ments, USA). The recordings of mEPSCs were performed
at −70mV using an internal solution containing the fol-
lowing (in mM): CsMeSO4 125, NaCl 8, HEPES 10, EGTA
5, Qx-314 1, Mg-ATP 4, and Na-GTP 0.5 (pH 7.2). The
bathing solution contained the following (in mM): NaCl
140, KCl 2.5, CaCl2 1.8, MgCl2 1, HEPES 10 and glucose
15 (pH 7.4) plus 1 μM tetrodotoxin, and 100 μM picro-
toxin (Tocris, UK). All experiments were performed at RT
(22–25 °C). The currents were filtered at 1–10 kHz (2-
pole Butterworth filter, −12 dB/octave, or low-pass Bessel
filter) and digitized at a sampling rate of 20 kHz to a
personal computer to be analyzed with pClamp software
(AXON Instruments, USA).
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KA-induced neurodegeneration in vivo
Male Wistar rats (weighting 250–300 g) were subjected
to intraperitoneal administration of KA (10 mg/kg) or
vehicle (0.9% NaCl). Fifteen minutes before, the animals
were administered with a single i.c.v. injection of
MRS2500 (1 nmol; Tocris) or artificial cerebrospinal fluid
(in mM: NaCl 124, KCl 3, NaH2PO4 1.25, NaHCO3 26,
MgCl2 1, CaCl2 2 and glucose 10) through a guide cannula
previously implanted into the lateral ventricle at the fol-
lowing coordinates relative to Bregma: −0.8 mm antero-
posterior; −1.5 mm lateral, and −3.5 mm dorso-ventral.
Administration was done at the rate of 0.5 μL/min. At the
end of the injection the needle remained in place for 3
min before being slowly removed from the cannula, to
avoid reflux. This dose of MRS2500 has been previously
validated in an in vivo model of brain ischemia15.
Seizure behavior was monitored for a 2-h period. Sei-
zures induced by KA (10 mg/kg, Sigma) were classified
into five stages according to the Racine’s scale27: stage I—
facial automatisms; stage II—head nodding; stage III—
forelimb clonus and lordotic posture; stage IV—forelimb
clonus as the animal rears; stage V—forelimb clonus and
rearing with falling over or loss of the righting reflex.
Stages III–V are considered motor or convulsive seizures
and should occur until 2 h after KA administration to
guarantee hippocampal neurodegeneration25. Hence, only
the animals reaching at least stage III of the Racine’s scale
were subjected to histological or biochemical analysis 24 h
later. For Western blot analysis, hippocampi were
removed and homogenized in a 0.32M sucrose solution
containing 1 mM EDTA, 10mM HEPES, and 1mg/mL
bovine serum albumin (BSA) (pH 7.4) at 4 °C. The
homogenates were centrifuged at 300 × g for 10 min at 4 °
C. The pellet was discarded and the supernatant was
further centrifuged at 100,000 × g for 30 min at 4 °C. The
supernatant was discarded and the pellet resuspended in
5% sodium dodecyl sulfate (SDS) solution with protease
inhibitors (Roche Diagnostics, Amadora, Portugal).
QA-induced neurodegeneration
Male Wistar rats (weighting 250–300 g) were placed in a
stereotaxic frame (Stoelting) connected to an anesthesia
system (EZ-7000 Classic System from E-Z Anesthesia,
Plexx B.V.) containing isoflurane (ISOFLO®, Esteve
Veterinaria, Spain), which maintained the animals anes-
thetized only during the stereotaxic procedure. Each
animal received a single unilateral intrahippocampal
injection (coordinates relative to Bregma: antero-posterior
−3.5 mm, lateral −2.5 mm, and dorso-ventral −4.0 mm)
of 1 µL at the rate of 0.2 µL/min controlled by an auto-
matic injector system (syringe pump, model 11 plus,
Harvard Apparatus), either of aCSF or of 120 nmol of QA.
Within each group, some of the animals were co-
administered 1 nmol of MRS2500. The osmolality of all
of the injected solutions was adjusted with NaCl. The
animals were monitored for convulsions for 2 h after the
intrahippocampal injections and the histological evalua-
tion was performed 24 h later.
FJC staining
For histological evaluation of the hippocampal neuro-
degeneration by FJC staining, brains were fixed through
transcardial perfusion and cut into 20-μm coronal sec-
tions comprising the whole hippocampus, using a cryostat
(CM3050 S from Leica Microsystems, Carnaxide, Portu-
gal). Brain slices were organized into series of 12 sections
separated successively by 240 µm, each series being
representative of all parts of the hippocampus. Brain
sections were defrost, dried, and immersed for 5 min in
0.01% NaOH prepared in an 80% ethanol solution. After
rising for 2 min in 70% ethanol and for 2 min in distilled
water, slices were transferred to a 0.06% potassium per-
manganate solution during 10 min, under constant agi-
tation and protected from light. Sections were again
rinsed in distilled water for 2 min and immersed in
0.0001% FJC (Histo-Chem Inc., USA) in 0.1% of acetic
acid for 10 min, protected from light and under agitation.
After three washing steps of 1 min with distilled water,
slices were dried on a slide warmer, dehydrated in an
ethanol gradient (50%, 70%, and 100%), and cleared in
xylene. Slices were then mounted in DPX non-aqueous
mounting medium (Merck, Algés, Portugal). Images were
acquired in a Zeiss Imager.Z2 microscope using the
Axiovision SE64 Rel. 4.8 software. FJC-positive cells of
complete series containing the hippocampus of each rat
(12 sections per series) were quantified using the cell
counter of the ImageJ 1.48v software.
Immunocytochemistry analysis
Rat hippocampal neurons were fixed with 4% paraf-
ormaldehyde in 0.9% NaCl and 4% sucrose solution for 30
min and permeabilized with PBS 0.2% Triton X-100 for
10min. The cells were then blocked with PBS 3% BSA for
30min to prevent non-specific binding and then incu-
bated with the primary antibodies in blocking solution for
1 h at room temperature. Hippocampal neurons were
immunolabeled with a rabbit polyclonal anti-P2Y1R
(1:200, Abcam, UK, Cat#ab104616 RRID:AB_10863775),
mouse monoclonal anti-synaptophysin (1:200, Sigma,
Cat#S5768, RRID:AB_477523), mouse monoclonal anti-
SMI31 (1:1000, Covance; LusoPalex, Sintra, Portugal,
Cat#SMI-31R-100, RRID:AB_10122491), chicken poly-
clonal anti-MAP2 (1:2500, Abcam, Cat#ab92434, RRID:
AB_2138147) and/or rabbit polyclonal antibody directed
against calpain-mediated SBDPs (1:300; Bahr et al.36).
Next, the cells were incubated with AlexaFluor-488-
conjugated donkey anti-mouse (1:400), AlexaFluor-555-
conjugated goat anti-rabbit (1:400), and AlexaFluor-633-
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conjugated goat anti-chicken (1:400) in blocking solution
for 1 h at room temperature. Coverslips were then
mounted on glass slides using DAPI (4',6-diamidino-2-
phenylindole)-supplemented mounting medium (Vecta-
shield, Vector Laboratories, Baptista Marques, Lisboa,
Portugal), cells were visualized using a laser scanning
Zeiss LSM 510 Meta confocal microscope and images
processed with ImageJ 1.48v software. Quantitative mor-
phological analysis of the density of synaptophysin puncta
per dendritic length was performed using Neurolucida
software (MBF Bioscience, Netherlands) analyzing a
minimum of 2000 µm of MAP2+ structures from two
coverslips per condition per culture. The fluorescence
intensity measurements of SMI31, SBDPs, and MAP2
were performed using ImageJ software. The fluorescence
intensities from the 8-bit images (256-color scale) were
directly converted into a 0–1 scale, being the absence of
fluorescence set as 0 and the maximum intensity set as 1.
Western blot analysis
Protein extracts from cultured hippocampal neurons or
hippocampal homogenates were diluted in 6× sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer ((0.5M Tris, 0.4% SDS, pH 6.8), 30%
glycerol, 10% SDS, 0.6M dithiothreitol, and 0.012% of
bromophenol blue), boiled at 95 °C for 5 min and then
separated by 10% SDS-PAGE electrophoresis. After the
electrotransfer of the proteins, CRMP2 protein was
detected using a rabbit antibody directed against CRMP2
(1:500; Abcam, Cat#ab36201, RRID:AB_731750) and the
different synaptic markers were detected using mouse
monoclonal antibodies directed against PSD-95 (1:20,000;
Millipore, Merck, Cat#P246, RRID:AB_260911), synapto-
physin (1:2000–1:20,000; Sigma, Cat#S5768, RRID:
AB_477523), and syntaxin 1 A (1:2000; Sigma, Cat#S0664,
RRID:AB_477483), guinea-pig polyclonal anti-vGluT1
(1:10,000; Synaptic Systems, Goettingen, Germany,
Cat#135304 RRID:AB_887878), anti-vGAT (1:1000;
Synaptic Systems; Cat#131004, RRID:AB_887873), and
rabbit polyclonal anti-gephyrin (1:10,000; Abcam,
Cat#ab25784 RRID:AB_1209349), all diluted in TBS-T
(Tris-buffered saline, 0.1% Tween 20) containing 5% dried
milk. Spectrin was detected using a mouse antibody
directed against Spectrin α-chain (1:500; Millipore,
Cat#MAB1622, RRID:AB_94295) diluted in TBS-T con-
taining 5% BSA. A rabbit antibody directed against
GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
(1:1000; Abcam, Cat#ab9485 RRID:AB_307275) and
mouse monoclonal antibodies against α-tubulin (1:20 000;
Sigma, Cat#T6074 RRID:AB_477582) or β-actin (1:20,000;
Sigma, Cat#A5316 RRID:AB_476743) were used as load-
ing controls. The membranes were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit
or goat anti-mouse or goat anti-guinea-pig secondary
antibodies (1:10,000; Pierce) and subsequently with
SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Alfagene) or with Luminata Forte Western HRP
Substrate (Millipore). The immunoreactivity was visua-
lized using a VersaDoc3000 apparatus and analyzed using
the ImageLab software (BioRad, Amadora, Portugal).
[3H]Aspartic acid-binding assay
Percoll-purified synaptosomes prepared as previously
described18 were resuspended in 15mL hyposmolar
binding assay medium (Tris/HCl, 50 mM; MgCl2, 3 mM;
CaCl2, 1 µM; Na2EDTA, 2 mM; protease inhibitor cocktail
(Sigma), 1 µL/mL, pH 7.4), and centrifuged at 20,000 g for
40 min to allow the separation of the synaptosomal
membranes. Next, these synaptosomal membranes were
diluted in the assay medium to reach ~1mg/mL protein
concentration, and 100 µL aliquots of this suspension
were mixed with 100 µL assay medium with or without
the selective antagonist of NMDARs D-AP-5 (30 μM,
Tocris) to determine non-NMDAR binding, and with or
without one of the following two selective antagonists of
P2Y1R, MRS2179 (10 µM), or MRS2500 (10 µM) (Tocris).
Finally, the 200 µL protein–receptor ligand mix was
combined with a third aliquot of 100 µL containing [3H]
aspartic acid (specific activity: 11.3 mCi/mM; Perki-
nElmer). The tested final concentrations (3–300 nM) of
[3H]aspartic acid were chosen based on a previous
NMDAR binding study in rat brain61. Each drug combi-
nation paired with each radioligand concentration was
carried out in duplicate in 6–7 rats. After leaving the 300
µL mixtures in the bottom of 15mL volume glass test
tubes for 30min at room temperature, they were rapidly
rinsed in 10mL ice-cold assay medium, and instantly
vacuum-filtered onto Whatman GF/B borosilicate filters
(Sigma). Filters were then collected and the radioactivity
retention was counted with a Tricarb β-counter (Perki-
nElmer). Bmax and KD were calculated from the specific
binding data with the help of GraphPad Prism.
Statistical analysis
All data are presented as the mean ± SEM of n experi-
ments. Group differences were analyzed using a two-
tailed unpaired t test (comparison of two independent
groups) or one-way analysis of variance (ANOVA)
(comparison of several independent groups). Where
ANOVA revealed significant general group effects, Dun-
net’s post hoc test was used to compare different groups
with the control group and Sidak’s post hoc test were used
for multiple comparisons. Modifications in the frequency
of mEPSCs were analyzed by Kruskal–Wallis test with
Dunn’s multiple comparison post hoc test. The effect of
the MRS2500 in the KA-induced cleavage of spectrin and
CRMP2 was appraised by two-way ANOVA. The com-
parison of the impact of MRS2500 in the cell death
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induced by the exposure for 30min and for 12 h to
NMDA (100 µM) was evaluated by two-way ANOVA with
Sidak’s multicomparison test. The extracellular levels of
ATP in culture, the protein densities determined in
Western blot analysis and the MTT reduction were
expressed either as the fold change or relative percentage
vs. control conditions. These relative differences were
analyzed by one-sample t test by comparison with a
hypothetical value of 1 or 100 (control condition). The
average fluorescence intensities of SMI31 in segments
without vs. with SBDP immunoreactivity were analyzed
with Mann–Whitney test. In all analyses performed, a
family-wise 95% confidence level (p < 0.05) was applied.
All data processing and analyses were performed using
the Prism 6.0 software (GraphPad).
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